CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.

Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 03; 9:46.

View in: PubMed

subject areas

Antineoplastic Agents
Apoptosis
Breast Neoplasms
Cell Movement
Cell Survival
Chemokines, CC
Cisplatin
Drug Resistance, Neoplasm
Focal Adhesion Kinase 1
Humans
Neoplasm Invasiveness
Proto-Oncogene Proteins c-akt
Receptors, CCR
Tumor Cells, Cultured

authors with profiles

James Lillard
Shailesh Singh
Rajesh Singh

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support